MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process

Using artificial intelligence to enhance data on clinical trial outcomes can help biomedical firms, investors, and — ultimately — patients.